<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361007</url>
  </required_header>
  <id_info>
    <org_study_id>WUM-CCA</org_study_id>
    <nct_id>NCT03361007</nct_id>
  </id_info>
  <brief_title>Polish Registry of Common Carotid Artery Access for TAVI</brief_title>
  <acronym>POL-CAROTID</acronym>
  <official_title>Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Implantation Through Common Carotid Artery Access in Polish Population - Observational Multicenter Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) is valuable treatment option for patients, who
      are at the high risk of surgical aortic valve replacement (AVR). Majority of procedures are
      performed through femoral arteries, however in some this access cannot be applied. Common
      carotid artery is one of the alternative routes of delivering the device in those patients.
      Established registry aims at collecting the data prospectively to assess outcomes of TAVI
      through common carotid artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective multicenter evaluation of transcatheter aortic valve implantations
      through common carotid artery in Polish health centers.

      Duration of this study is expected to be 6 years to ensure that all of the enrolled patients
      will complete at least 2 years of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>VARC (Valve Academic Research Consortium-2) defined &quot;Clinical Efficacy&quot; composite endpoint</measure>
    <time_frame>From 30 days post procedure to completion of at least 2 years of follow up</time_frame>
    <description>All-cause mortality
All stroke (disabling and non-disabling)
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure
NYHA (New York Heart Association) class III or IV functional classification of heart failure
Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, Effective Orifice Area (EOA) ≤0.9-1.1 cm2(c) and/or Doppler Velocity Integral (DVI) &lt;0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VARC defined 'Device success' composite endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of procedural mortality AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location AND
Intended performance of the prosthetic heart valve (no prosthesis - patient mismatch and mean aortic valve gradient ,20 mmHg or peak velocity ,3 m/s, AND no moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC defined &quot;Early Safety&quot; composite endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury—Stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (Balloon Aortic Valvuloplasty (BAV), Trans Catheter Aortic Valve Implant (TAVI), or Surgical Aortic Valve Replacement (SAVR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC defined &quot;Time-related valve safety&quot; composite endpoint</measure>
    <time_frame>From device implant to completion of at least 2 years of follow up</time_frame>
    <description>Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2cand/or DVI &lt;0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)
Requiring repeat procedure (TAVI or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thrombo-embolic events (e.g. stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Ventricular Outflow Obstruction, Left</condition>
  <arm_group>
    <arm_group_label>Common carotid artery access for TAVI</arm_group_label>
    <description>Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation (TAVI)</intervention_name>
    <description>Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.</description>
    <arm_group_label>Common carotid artery access for TAVI</arm_group_label>
    <other_name>Transcatheter Aortic Valve Replacement (TAVR)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients meeting inclusion criteria will prospectively included in the study. Patients
        meeting inclusion criteria before the set-up of registry will be included retrospectively.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Qualification for TAVI through common carotid artery by decision of the local Heart
             Team

          -  Patient provided written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zenon Huczek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radosław Wilimski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kajetan Grodecki</last_name>
    <phone>+48660675782</phone>
    <email>kajetan.grodecki@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Jagielak, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Wojakowski, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Opole</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerzy Sacha, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Grygier, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zenon Huczek, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kajetan Grodecki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Walczak, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Huczek Z, Wilimski R, Kochman J, Szczudlik P, Scisło P, Rymuza B, Kapłon-Cieślicka A, Kolasa A, Marchel M, Filipiak KJ, Cichoń R, Opolski G. Common carotid artery access for transcatheter aortic valve implantation. Kardiol Pol. 2015;73(7):478-84. doi: 10.5603/KP.2015.0122.</citation>
    <PMID>26189468</PMID>
  </reference>
  <reference>
    <citation>Azmoun A, Amabile N, Ramadan R, Ghostine S, Caussin C, Fradi S, Raoux F, Brenot P, Nottin R, Deleuze P. Transcatheter aortic valve implantation through carotid artery access under local anaesthesia. Eur J Cardiothorac Surg. 2014 Oct;46(4):693-8; discussion 698. doi: 10.1093/ejcts/ezt619. Epub 2014 Jan 14.</citation>
    <PMID>24431170</PMID>
  </reference>
  <reference>
    <citation>Schirmer J, Conradi L, Seiffert M, Koschyk D, Blankenberg S, Reichenspurner H, Diemert P, Treede H. Transcatheter aortic valve implantation: alternative access options. Minerva Cardioangiol. 2013 Aug;61(4):429-35. Review.</citation>
    <PMID>23846009</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>common carotid artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

